Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Davita Inc (DVA) vs GeneDx Holdings Corp (WGS) Price & Performance

Davita IncTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Davita Inc vs GeneDx Holdings Corp — how do they compare? Davita Inc trades at $179.02 (market cap $11.72B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: Davita Inc is far larger — about 5.1× GeneDx Holdings Corp's market cap, and Davita Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

DVAWGS
Market Cap
$11.72B$2.32B
Sector
HealthTechnology
52-Week High
$240.96$167.51
52-Week Low
$103.87$34.51
Enterprise Value
$24.44B$2.35B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Davita Inc

DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.

The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.

Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Davita Inc

DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.

Read more on DVA

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS